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Abstract
Backgrounds
TheWomen's Health Initiative Memory Study Magnetic Resonance Imaging (WHIMS-MRI)
provides an opportunity to evaluate how menopausal hormone therapy (HT) affects the
structure of older women’s brains. Our earlier work based on region of interest (ROI) analy-
sis demonstrated potential structural changes underlying adverse effects of HT on cogni-
tion. However, the ROI-based analysis is limited in statistical power and precision, and
cannot provide fine-grained mapping of whole-brain changes.
Methods
We aimed to identify local structural differences between HT and placebo groups from
WHIMS-MRI in a whole-brain refined level, by using a novel method, named Optimally-Dis-
criminative Voxel-Based Analysis (ODVBA). ODVBA is a recently proposed imaging pattern
analysis approach for group comparisons utilizing a spatially adaptive analysis scheme to
accurately locate areas of group differences, thereby providing superior sensitivity and
specificity to detect the structural brain changes over conventional methods.
Results
Women assigned to HT treatments had significant Gray Matter (GM) losses compared to
the placebo groups in the anterior cingulate and the adjacent medial frontal gyrus, and the
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orbitofrontal cortex, which persisted after multiple comparison corrections. There were no
regions where HT was significantly associated with larger volumes compared to placebo,
although a trend of marginal significance was found in the posterior cingulate cortical area.
The CEE-Alone and CEE+MPA groups, although compared with different placebo controls,
demonstrated similar effects according to the spatial patterns of structural changes.
Conclusions
HT had adverse effects on GM volumes and risk for cognitive impairment and dementia in
older women. These findings advanced our understanding of the neurobiological underpin-
nings of HT effects.
Introduction
TheWomen’s Health Initiative Memory Study (WHIMS) provided a unique opportunity for
researchers to examine critical questions regarding the effects of hormone therapy (HT) on
brain structure of postmenopausal women. Results from the WHIMS study [1, 2, 3, 4] indi-
cated that conjugated equine estrogens, with and without progestin, increase the risk of demen-
tia and have adverse effects on cognition in women aged 65 and over.
Advances in Magnetic Resonance Imaging (MRI) make it possible to non-invasively and
sensitively measure pathologic changes in cortical and subcortical brain parenchyma.
WHIMS-MRI, as a sub-study of the Women’s Health Initiative (WHI) andWHIMS, was able
to provide a comprehensive examination of the effects of hormone therapy on regional brain
structure in postmenopausal women. In our earlier work [5], we investigated whether regions
of interest (ROI) including total brain, hippocampus, frontal lobe, and others labeled on MRI
scans acquired post-trial, show significant differences in volumes for older women who had
been assigned to HT compared with those assigned to placebo. The results suggested that
women assigned to HT had decreased volumes in specific regions compared with those
assigned to placebo, offering a potential mechanism underlying the adverse effects of HT on
cognition. However, the ROI-based analysis may lack statistical precision as it does not take
into account the complex and anisotropic structural information circumscribed by the brain
ROIs. Moreover, the outputs of the ROI analysis can only provide gross information on volu-
metric structure of particular regions, which cannot meet the current need of fine-grained
mapping of brain alterations.
The current study aimed to identify local structural differences between HT and placebo
groups fromWHIMS-MRI, using a voxel-wise method, which analyzes the whole brain auto-
matically, resulting in a brain map that reflects statistical significance on a refined level. Voxel-
Based Morphometry (VBM) [6, 7, 8] is one such technique, commonly used in past years for
mapping neuroanatomical differences including those associated with HT [9, 10, 11]. However,
the conventional VBMmethod has technical shortcomings. First, the general linear model
(GLM [12]) exploited in VBM has limited statistical power due to its mass-univariate nature
that discards complex multivariate relationships in the data [13]. Second, the Gaussian
smoothing, typically applied prior to the GLM step in VBM, has been shown to increase the
risk of both false positive and false negative results [14, 15, 16] due to its blurring effects on the
spatial signals of images.
In this study we used a novel method, termed optimally-discriminative voxel-based analysis
(ODVBA), which is a recently proposed imaging pattern analysis approach for group
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comparisons recently proposed by [17, 18]. ODVBA utilizes a spatially adaptive analysis
scheme to accurately locate areas of group differences, and thereby transcends the limitations
of the commonly used Gaussian smoothing with a fixed kernel size that precedes GLM, trans-
lating to superior sensitivity and specificity to detect the structural brain changes. The perfor-
mance of ODVBA has been extensively validated in both the simulated data in which the
ground truth on the simulated abnormalities is known [17] and the real data from clinical stud-
ies in Alzheimer's Disease [17, 18], schizophrenia [18, 19], ADHD [20], imaging effects of dia-
betes [21], among others. To our knowledge, the present study is the first voxel-based
morphometric study to investigate the structural brain changes associated with hormone ther-
apy in the WHIMS project.
Materials and Methods
Participants
As an ancillary study of WHI (registered at ClinicalTrials.gov with ID# NCT00000611),
WHIMS was conducted to investigate the effects of hormone therapy on risk of dementia and
changes in cognitive function in women aged 65 or older. Data are available fromWomen's
Health Initiative (www.whi.org), once a signed data use agreement is in place. For more details
refer to the associated Data Availability statement. The subjects were randomized into the par-
allel placebo-controlled randomized clinical trials of 0.625 mg/d conjugated equine estrogens
(CEE) therapy alone (CEE-Alone) and in combination with 2.5 mg/d medroxyprogesterone
acetate (CEE+MPA). The study protocols and consent forms were approved by National Insti-
tutes of Health and Institutional Review Boards of all 40 participating clinical centers (https://
www.nhlbi.nih.gov/whi/ccenterlist.htm). Written informed consent was obtained from each
participant. Participant records/information was anonymized and de-identified prior to analy-
sis. The details of this study were previously published [1, 2, 22].
The WHIMS-MRI trial, conducted at 14 of 39 WHIMS sites [5, 23], was designed to deter-
mine whether ischemic lesion volumes and volumes of brain parenchym differed between
women previously randomized to CEE-Alone and CEE+MPA and their respective placebo
groups. For the overall with trial, randomization was stratified by site to achieve balance.
Among participants included in our analysis, treatment assignments were balanced among
clinics (p = 0.32). The recruitment started in January 2005 and ended in April 2006, approxi-
mately 1.4 years for CEE-Alone and 3.0 years for CEE+MPA after the termination of the WHI
trial. Of the total sample of 1424 participants who completed the scanning, 1,365 participants
who met the reading criteria were included in this analysis, including 254 active and 256 pla-
cebo participants in the CEE-Alone trial, and 420 active and 435 placebo participants in the
CEE+MPA trial, making the total 674 HT and 691 placebo participants. The demographic, life-
style, and clinical characteristics of the women included in this study are listed in Table 1. As
demonstrated, there were no marked differences in the related risk factors between the active
treatment groups and the associated placebo.
Image Acquisition and Pre-Processing
MRI scans were performed using a standardized protocol which was developed by investigators
at the MRI Quality Control (QC) Center in the Department of Radiology of University of
Pennsylvania (UPenn). The scanners were standardized by American College of Radiology
(ACR) phantom QC protocol as follows. Before each clinical site can enroll subjects into
WHIMS study protocol, a set of test scans on the ACR QC phantoms [24] and a volunteer
have been be submitted for review and approved by the MRI QC Center in UPenn. The ACR
phantom tests have been performed on a quarterly basis. Details on procedures for acquisition
Effects of Hormone Therapy on Brain Volumes Changes
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Table 1. Demographic, lifestyle, and clinical characteristics of WHIMS-MRI women by treatment assignment.
Variable WHIMS-MRI: CEE-Alone WHIMS-MRI: CEE+MPA Statistics (p values, %)
CEE-Alone
(n = 254)
Placebo
(n = 256)
CEE+MPA
(n = 420)
Placebo
(n = 435)
CEE-Alone vs.
Placebo
CEE+MPA vs.
Placebo
HT vs.
Placebo
Age, no. (%) 90.82 87.94 87.33
65–69 y 123(48.43) 128(50.00) 220 (52.38) 225 (51.72)
70–74 y 93(36.61) 89 (34.77) 147 (35.00) 150 (34.48)
75 + y 38 (14.96) 39 (15.23) 53 (12.62) 60 (13.79)
Ethnicity 9.63 27.65 97.32
Black/African
American
13 (5.16) 16 (6.27) 17 (4.05) 15 (3.46)
White, non-Hispanic 222 (88.10) 232(90.98) 392 (93.33) 399 (91.94)
Other 17 (6.75) 7 (2.75) 11 (2.62) 22 (4.61)
Education 13.05 51.59 94.43
<High school 16 (6.30) 8 (3.13) 15 (3.58) 21 (4.85)
High school /GED 69 (27.17) 69 (26.95) 84 (20.05) 95 (21.94)
>High school, <4 y
college
94 (37.10) 115 (44.92) 174 (41.53) 161 (37.18)
>4 y college 75 (29.53) 64 (25.00) 146 (34.84) 156 (36.03)
Smoking Status 44.90 63.60 69.82
Never 147 (58.57) 142 (55.69) 248 (59.33) 247 (57.44)
Former 95 (37.85) 98 (38.43) 152 (36.36) 168 (39.07)
Current 9 (3.59) 15 (5.88) 18 (4.31) 15 (3.49)
Body Mass Index 77.45 69.06 73.06
<25 kg/m2 59 (23.41) 63 (24.71) 134 (31.98) 153 (35.25)
25–29 kg/m2 98 (38.89) 107 (41.96) 157 (37.47) 151 (34.79)
30–34 kg/m2 60 (23.81) 55 (21.57) 89 (21.24) 86 (19.82)
35 kg/m2 35 (13.89) 30 (11.76) 39 (9.31) 44 (10.14)
Hypertension Status 38.11 24.42 68.68
None 120 (47.24) 134 (52.34) 227 (54.05) 234 (53.79)
Current/controlled 51 (20.08) 53 (20.70) 53 (12.62) 45 (10.34)
Current/uncontrolled 83 (32.68) 69 (26.95) 140 (33.33) 156 (35.86)
Prior Cardiovascular
Disease
92.22 20.95 36.59
No 233 (91.73) 233 (91.02) 399 (95.00) 414 (95.17)
History of stroke 3 (1.18) 4 (1.56) 1 (0.24) 5 (1.15)
History of other CVD 18 (7.09) 19 (7.42) 20 (4.76) 16 (3.68)
Diabetes 49.72 36.05 22.47
No 238 (93.70) 235 (91.80) 405 (96.43) 414 (95.17)
Yes 16 (6.30) 21 (8.20) 15 (3.57) 21 (4.83)
Prior Hormone
Therapy
59.56 70.42 58.78
No 129 (50.79) 124 (48.44) 328 (78.10) 335 (77.01)
Yes 125 (49.21) 132 (51.56) 92 (21.90) 100 (22.99)
3MS score 77.10 46.60 38.40
<90 20 (7.94) 19 (7.48) 20 (4.77) 17 (3.96)
90–94 50 (19.84) 57 (22.44) 63 (15.04) 77 (17.95)
95–100 182 (74.22) 178 (70.08) 336 (80.19) 335 (78.09)
doi:10.1371/journal.pone.0150834.t001
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and processing were provided previously [5, 25]. Briefly, the scans were obtained with a field of
view = 22 cm and a matrix of 256×256. Included were oblique axial spin density/T2-weighted
spin echo (TR:3200 ms, TE = 30/120 ms, slice thickness = 3 mm), fluid-attenuated inversion
recovery (FLAIR) T2-weighted spin echo (TR = 8000 ms, TI = 2000 ms, TE = 100 ms, slice
thickness = 3 mm), and oblique axial three-dimensional T1-weighted gradient echo (flip
angle = 30 degrees, TR = 21 ms, TE = 8 ms, slice thickness = 1.5 mm) images from the vertex to
the skull base parallel to the anterior commissure–posterior commissure (AC-PC) plane.
The T1-weighted images were preprocessed according to a number of steps including 1)
alignment of the brain with the AC-PC plane by manually; 2) removal of extra-cranial material
using the BET method [26]; 3) tissue segmentation into gray matter (GM), white matter
(WM), and cerebrospinal fluid (CSF), using a method described in [27]; 4) high-dimensional
image warping to a standard MNI space [28], through an elastic registration method [29]; 5)
applying the deformation field that resulted from the spatial registration to the segmented
images, thereby generating mass-preserved volumetric maps (or tissue density maps), named
Regional Analysis of Volumes Examined in Normalized Space (RAVENS) maps (Davatzikos
et al., 2001); and 6) correction for the effects of i) intracranial volume (ICV), ii) age, iii) clinic
site, and iv) time from randomization to scan, using the multiple linear regression model [30].
Statistical Analysis
Group comparisons were performed via voxel-based statistical analysis of the volumetric mea-
surements by using ODVBA. The ODVBA software is freely available (https://www.cbica.
upenn.edu/sbia/software/odvba/) under a BSD-style open source license. ODVBA is a recently
proposed imaging pattern analysis framework used to more accurately detect the group differ-
ences in brain imaging data. ODVBA starts with the regional multivariate discriminative analy-
ses with a non-negativity constraint, as an optimal anisotropic filtering of images that enhances
group differences. Next, the whole brain map of statistic is calculated by tallying the weights of
each voxel to all of the neighborhoods in which it belongs. Finally, the statistical significance
maps are obtained via nonparametric permutation testing [31]: assuming that the null hypoth-
esis is that there is no difference between two groups, the p value of each voxel is calculated by
comparing the observed statistic to the random permutation distribution. The current study
used 2,000 permutations to derive the significances.
To address the multiple-comparison problem, we implemented cluster-wise Family Wise
Error (FWE) correction based on non-parametric permutation tests [31, 32, 33]. The cluster-
wise FWE is reported to be more powerful [32] than the voxel-wise False Discovery Rate (FDR)
correction [34, 35], because it takes into account the spatial correlations [33] within regional vol-
umes. The resulting maps of significance were partitioned and analyzed according to the Auto-
mated Anatomical Labeling (AAL) package [36]. On each anatomical region, we calculated the
cluster size, the t statistic (based on the means of the tissue density of the detected area per region,
as well as in [17]), and the Talairach coordinate of the mass’s center [37].
Results
GM Findings
HT, CEE-Alone, and CEE+MPA< Placebo. As shown in Fig 1 and Table 2, women
assigned to HT (both CEE-Alone and CEE+MPA users) showed significantly less GM com-
pared to those assigned to placebo in the medial prefrontal regions, including the bilateral ante-
rior cingulate cortex (p<0.05, FWE corrected) and the adjacent bilateral superior frontal gyrus
(p<0.05, FWE corrected) as well as the bilateral middle cingulate cortex (p<0.05, FWE
Effects of Hormone Therapy on Brain Volumes Changes
PLOS ONE | DOI:10.1371/journal.pone.0150834 March 14, 2016 5 / 16
Fig 1. 3D surface renderings (upper six images) and representative slices (lower six images) of the ODVBA results on GM volumes comparisons
of HT groups < Placebo.Green indicates the detected significant regions with FWE corrected p < 0.05; regions of hot colors indicate the trends (uncorrected
p < 0.05) towards significance characterized by the–log (p) values shown in the colorbar.
doi:10.1371/journal.pone.0150834.g001
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corrected), and in the ventromedial prefrontal regions including the orbitofrontal cortex (bilat-
eral: p<0.05, FWE corrected) and the gyrus rectus (bilateral: p<0.05, FWE corrected).
The comparison between CEE-Alone treated women and their respective placebo group
revealed significantly lower GM volumes in the CEE-Alone group, which were predominantly
located in the bilateral anterior cingulate cortex (p<0.05, FWE corrected), the bilateral medial
part of the superior frontal gyrus (p<0.05, FWE corrected).
The CEE+MPA group did not show regions of significantly decreased GM volumes with mul-
tiple comparison correction, relative to the matched placebo, but did demonstrate trends toward
lower volumes with a liberal uncorrected significance level (S1 Table) in the prefrontal cortex, in
accord with the findings in the previous two comparisons. Moreover, all three comparisons
revealed trend level volume reductions in left-sided temporal lobe structures (as shown in Fig 1
and S1 Table), including inferior temporal gyrus, parahippocampal gyrus, hippocampus, etc.
HT, CEE-Alone, CEE+MPA> Placebo. There were no significant differences indicative
of greater volumes associated with HT surviving the multiple-comparison corrections, but
three comparisons showed trends (Fig 2, S1 Table) for the parietal/occipital area, including the
right calcarine, the right precuneus, and the left middle occipital gyrus.
WMFindings
Analysis of local WM volumes revealed no significant differences after multiple comparison
correction when comparisons were performed between HT, CEE-Alone, CEE+MPA and the
respective placebo groups. However, as demonstrated in Fig 3 and S2 Table, we detected trends
that were generally consistent with our findings in GM. Specifically, all three comparisons of
HT, CEE-Alone, and CEE+MPA< Placebo showed consistently lower HT-associated WM
volumes in regions around the bilateral medial frontal lobe, the bilateral orbitofrontal cortex,
and the left temporal lobe. We also found trends toward greater HT-associated WM for all
three comparisons for the parietal/occipital area.
Table 2. The results of GM volume comparisons of HT groups < Placebo.N denotes the number of significant voxels in each anatomical region. t
denotes the t value calculated.
Comparisons Methods Anatomical Regions Side Talairach coordinates N t
x y z
HT < Placebo FWE(p < .05)
Anterior Cingulate Cortex L -3.96 35.70 14.79 651 4.74
Medial Superior Frontal Gyrus L -3.96 40.13 25.63 449 6.21
Orbitofrontal Cortex L -3.96 49.96 -10.91 448 4.21
Gyrus Rectus L -1.98 39.85 -18.82 333 3.98
Gyrus Rectus R 5.94 35.97 -18.62 186 4.89
Anterior Cingulate Cortex R 5.94 33.86 16.73 169 4.86
Orbitofrontal Cortex R 15.84 37.83 -20.40 95 3.80
Middle Cingulate Cortex R 5.94 28.60 28.05 49 2.98
Middle Cingulate Cortex L -3.96 22.88 30.17 25 2.57
Superior Frontal Gyrus L -11.88 28.87 33.56 11 2.84
CEE-Alone < Placebo FWE(p < .05)
Anterior Cingulate Cortex L -3.96 33.77 14.89 491 4.62
Medial Superior Frontal Gyrus L -1.98 43.82 21.76 329 5.64
Anterior Cingulate Cortex R 5.94 37.55 12.86 204 5.74
Medial Superior Frontal Gyrus R 5.94 50.56 1.15 79 4.12
Middle Cingulate Cortex R 7.92 34.41 27.75 14 3.51
doi:10.1371/journal.pone.0150834.t002
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Fig 2. 3D surface renderings (upper six images) and representative slices (lower six images) of the ODVBA results on GM volume comparisons of
HT groups > Placebo.Regions of hot colors indicate trends (uncorrected p < 0.05) towards significance characterized by the–log (p) values shown in the
colorbar.
doi:10.1371/journal.pone.0150834.g002
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Other Analyses
CEE-Alone versus CEE+MPA. CEE-Alone and CEE+MPA groups cannot be contrasted
directly due to differences in their demographic and medical characteristics, requiring separate
placebo groups for the two trials. In Fig 4, we demonstrate the overlap of significant findings
for GM andWM (regions in red).
Sensitivity analysis. As women with other vulnerabilities may be more sensitive to the
effects of HT, we recalculated outcomes by excluding women with low baseline cognition (3MS
score< 90; 20 CEE subjects and 19 associated placebo; 20 CEE+MPA subjects and 17 associ-
ated placebo) and with diabetes (16 CEE subjects and 21 associated placebo; 15 CEE+MPA
subjects and 21 associated placebo), which are with small numbers though. This can be
regarded as a kind of sensitivity analysis that generally investigates how the uncertainty in the
output of a model or system can be distributed to different sources of inputs [38]. The results
indicated that the group analyses excluding women with these vulnerabilities yielded the nearly
the same patterns with those of the original analyses.
Discussions
In WHIMS-MRI, we assessed the effects of postmenopausal HT on localized brain volume
changes in a large sample of older women in the context of the WHI randomized clinical trials.
Women had been previously assigned to either CEE-Alone or CEE+MPA and their respective
placebos, allowing investigation of effects of postmenopausal hormone therapy using a novel
voxel-based morphometric method to investigate effects across the entire brain. These analyses
Fig 3. Representative slices of the ODVBA results on WM volume comparisons of (A) HT groups < Placebo, and (B) HT groups > Placebo. Regions of hot
colors indicate trends (uncorrected p < 0.05) towards significance characterized by the–log (p) values shown in the colorbar.
doi:10.1371/journal.pone.0150834.g003
Effects of Hormone Therapy on Brain Volumes Changes
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Fig 4. Representative slices of the results of CEE-Alone vs Placebo (light blue) and CEE+MPA vs Placebo (green) on the one standard template.
The detected regions are with threshold of uncorrected p < 0.05. Red represents the overlap of results between the two methods.
doi:10.1371/journal.pone.0150834.g004
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demonstrated significant regions of HT-associated reductions in brain volume, providing fur-
ther insights into our understanding of the neurobiological underpinnings of HT effects.
A widespread pattern of significant volume loss was detected in women undergoing HT
treatments mainly in the anterior cingulate and the adjacent medial frontal gyrus, and the orbi-
tofrontal cortex. Both anterior cingulate and orbitofrontal cortex are key components of the
rostral limbic system [39, 40], which are part of a neural circuit consisting of the anterior com-
ponent of the limbic system. These structures interface with limbic, executive, and behavioral
structures that are involved in the motivational evaluation of stimuli. The two regions and their
dense connections are associated with higher-level functions such as decision-making [41, 42,
43] and emotional regulation [44, 45]. The anterior cingulate cortex in particular is involved in
the ongoing information processing of cognitive resource allocation [46, 47], that is, “cognitive
control” [48]. Impairment of the anterior cingulate cortex and the orbitofrontal cortex has
been identified in patients with various types of dementia, including frontotemporal dementia
[40, 49], vascular dementia [50, 51] and an agitation subgroup [52] of Alzheimer’s disease
(AD).
Temporal lobe structures showing HT-associated adverse effects at the trend level include
hippocampus, parahippocampal gyrus, inferior temporal gyrus, and the middle temporal
gyrus. The integrity of temporal lobe structures, especially those in the medial aspect of the
temporal lobe, are critical to the maintenance of memory function. Medial temporal regions
are the earliest to show the neurofibrillary tangle pathology of AD [53, 54] which then spreads
to adjacent neocortical areas.
Our current findings are consistent with HT-associated GM reductions demonstrated in
our previous WHIMS-MRI studies based on region of interest analysis [5]. In our earlier
report, we showed that CEE, with or without MPA, was associated with small but significant
decrements in hippocampal and frontal regions. However, our study have provided more accu-
rate localizations of brain volume changes and more refined significance levels across regions,
by leveraging on the voxel-wise analysis and multiple comparisons. A follow-up pattern classi-
fication analysis [55] selected the most discriminative regions for the classification task and
identified associations between CEE-Alone therapy and smaller regional volumes, including
inferior temporal gyrus and vicinities of the hippocampus, including the perirhinal cortex and
the entorhinal cortex. Moreover, our finding of the adverse effect of HT on brain volume is
consistent with a VBM study on a different dataset [11]: in an observational study comparing
HT users versus nonusers, Lord and colleagues demonstrated reductions in hippocampal and
parahippocampal gyrus volumes in HT users.
In contrast to our findings of multiple regions of HT-associated volume reductions, we
found no significant regions where HT was associated with larger volumes compared to pla-
cebo. However, at the trend level we found larger volumes in the HT group for the posterior
cingulate cortical (PCC) area, including the precuneus and the adjacent calcarine fissure. The
PCC/precuneus is a key part of the default mode network [56], which is thought to be impor-
tant for self-referential [57] and episodic memory [58]. Our findings regarding the PCC area
are partially in accordance with the results of the previous studies. An early VBM study com-
paring HT users versus nonusers [10] identified the posterior cingulate gyrus as a region exhib-
iting larger volumes among younger estrogen users–women around 50 years old. The pattern
classification based study of WHIMS on CEE-Alone versus placebo [55] also identified parietal
lobe regions where the CEE group had slightly larger volumes. Further a functional MRI study
[59] reported higher posterior cingulate activation in hormone users compared with nonusers
during a visual working memory task.
The CEE-Alone and CEE+MPA groups, although compared with different placebo controls,
demonstrated similar effects of hormone therapy according to the spatial patterns of structural
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changes. In Fig 4, we overlaid the results of CEE-Alone and CEE+MPA groups in a single stan-
dard template, highlighting regions where the two HT groups share similar structural differ-
ences in association with the different interventions. This overlap was most evident in the
prefrontal and hippocampal regions, indicating regions of HT-associated GM volume reduc-
tions, and in the PCC area which showed higher GM volume in the HT compared with placebo
groups. These regions of overlap were consistent with our overall analysis comparing HT vs.
placebo, which combined women across both the CEE-Alone and CEE+MPA trials.
Taken together, the most robust findings in our study, which survived more stringent statis-
tical correction, primarily revealed the adverse effect of HT on GM volumes and risk for cogni-
tive impairment and dementia in older women, consistent with prior literature [1, 2, 3, 4, 5, 11,
55, 60, 61, 62]. However, other studies have reported beneficial effects of HT. Two VBM studies
[9, 10] indicated higher GM volume in HT users compared with nonusers, which were found
widely across the brain gray matter surface. In addition, a few functional neuroimaging studies
[59, 63, 64] have also demonstrated that HT can play neuroprotective effects against aging or
cognitive decline. However, the majority of studies demonstrating benefits are based on obser-
vational studies or studies in younger postmenopausal women. Discrepancies may reflect dif-
ferent experimental strategies and methods used in these studies, as well as differences in the
timing of initiation with respect to age and/or the menopausal transition. It should be noted
that most studies showing the neuroprotective effects enrolled younger women for their experi-
ments and may reflect a critical window for HT action [65, 66, 67].
Our study involves multiple sites, as most large scale clinical trials do. We promoted stan-
dardization across different sites using the ACR phantom QC protocols. The phantom tests
have been performed based on a series of measurements, including geometric accuracy, low
contrast detectability, high contrast spatial resolution, slice thickness, ghosting artifacts, and
more. This phantom test procedure has been a useful method to evaluate the performance of
the MRI system, and to determine whether corrective actions are successful. For example, the
geometric accuracy test can help to identify gradient mis-calibration and too-low acquisition
bandwidth. In addition, after image acquisition, we used the general linear regression model
(GLM) as a preprocessing step to further remove the effects of the different clinical sites. Dis-
persion [68] of different sites can be defined as follows: first, we calculate the sample mean of
the whole GM/WM volume values for each site. Next, we calculated the measures of dispersion
according to a number of statistics on the sample means, resulting in interquartile range (IQR),
mean absolute deviation (MAD), range, and standard deviation (STD). S1 Fig demonstrated
the measures of dispersion of different sites, calculated before and after removing the site
effects respectively. As shown, the covariance correction has reduced the dispersion of different
sites.
Our future work aims to investigate the use of our optimally-discriminative voxel-based
morphometric method to study the rate of decline in brain volumes during 4.7 years between
the initial and follow-up [69] WHIMS-MRI studies, and also to examine whether the effect of
HT on rate of decline differs depending on specific vulnerabilities, e.g. low cognitive function,
increased vascular risk, and diabetes.
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